Journal of medical toxicology : official journal of the American College of Medical Toxicology
June 1, 2013
Adam Bosak, Frank Lovecchio, Michael Levine
59 citations
A 19-year-old male who insufflated the designer drug 2C-I developed recurrent seizures, hyperadrenergic state, and serotonin syndrome, leading to prolonged respiratory failure. Comprehensive drug testing confirmed 2C-I. The patient ultimately made a full recovery. This case highlights the potential for severe toxicity from this emerging phenethylamine, with effects including seizures and serotonin syndrome, and underscores the need for awareness among clinicians.
Journal of psychopharmacology (Oxford, England)
May 1, 2025
Sean P Goldy, Benjamin A Du, Julia S Rohde et al.
15 citations
Classic psychedelics carry both greater acute challenging effects and persisting negative effects compared to cannabis, but also produce greater positive acute and persisting effects. In two studies using quota-based sampling to approximate US Census demographics, participants reported on their first or most memorable experiences with either substance. Predictors of psychedelic outcomes—such as dose level, presence of others, religiosity, and personality—explained only a small degree of the variation. The findings offer a more nuanced characterization of the risks and benefits of psychedelic experiences relative to cannabis.
Psychedelic Medicine
February 7, 2025
Jérémie Richard, Michael Levine
12 citations
Psychological support in psychedelic clinical trials is poorly defined, with little agreement on its essential components, boundaries, or limits. This perspective article proposes using the microskills framework from Ivey et al. (2021) to distinguish psychological support from psychotherapy by focusing on specific communication units and behaviors. The authors argue that trial protocols and treatment manuals should clearly define which psychosocial interventions and behaviors are permitted, to prevent interventions that exceed the trial's mandate or the session monitor's regulatory scope of practice.
Pharmacological research
January 1, 2024
David B Yaden, Andrea P Berghella, Peter S Hendricks et al.
12 citations
Classic psychedelic-assisted therapies show initial promise for treating substance use disorders (SUDs) and may become legally available options. This article describes how these therapies could fit within current evidence-based SUD treatments, suggesting broad compatibility with most mainstream clinical approaches.